Dialog Box

Loading...

Melbourne Patient & Carer Education Day

 

Follicular Lymphoma & Waldenstrom's (WM)

Professor Mathias Rummel from Germany, is a world expert in indolent (slow growing lymphomas) and he will be in Melbourne on Monday the 25th of March.

Patients, carers and interested health professionals are welcome to join us at Monash Health (Clayton Campus) for what will be a very informative session on Follicular and Wadenstroms Macroglobulinemia (WM) 

When:  Monday 25th March 2019

Where: Monash Health Clayton Campus, Wellington Road Clayton  

MHTP Building, TRF, Level 2, Seminar Room 3    

Map:  Finding the room at Monash.pdf

Time: 1.30pm arrive 2pm  - 3.30pm (afternoon tea will be available )

The presentation will focus on:  

  • Current treatment options   
  • New and emerging therapies for follicular and Waldenstrom's Macroglobulinemia
  • Your Questions Answered  

It is FREE to attend - please register by completing the form below.  

About Professor Mathias Rummel

Mathias Rummel, MD, is a Professor of Medicine and is the director of the Department for Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital in Giessen, Germany. His current research focuses on novel treatment approaches in hematological malignancies, most notably Follicular Lymphoma, Mantle Cell Lymphoma, Waldenström’s Macroglobulinemia and other indolent lymphomas as well as Chronic Lymphocytic Leukemia (CLL), Hairy CellLeukemia and also in the non-malignant hematological disorder Immune Thrombocytopenia (ITP)

He is the chair of the large cooperative German Study group indolent Lymphomas (StiL) with more than 220 study sites in Germany and Austria and is the principal investigator of several on-going clinical protocols, in particular of Investigator Initiated Trials (IIT).Professor Rummel is actively involved in a number of professional scientific societies, including the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the European Haematology Association (EHA), and the German Society of Haematology and Oncology (DGHO). He is the principal investigator of many clinical trials in Leukemias, Lymphomas, Hairy Cell Leukemia, and Immune Thrombocytopenia (ITP), and has published several book chapters and papers in peer reviewed scientific journals.